2M41 image
Deposition Date 2013-01-28
Release Date 2013-12-11
Last Version Date 2024-05-15
Entry Detail
PDB ID:
2M41
Title:
Solution Structure of the AXH domain of Ataxin-1 in complex with ligand peptide from Capicua
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Conformers Calculated:
200
Conformers Submitted:
15
Selection Criteria:
structures with the lowest energy
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Protein capicua homolog
Gene (Uniprot):CIC
Chain IDs:A
Chain Length:15
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Ataxin-1
Gene (Uniprot):ATXN1
Chain IDs:B
Chain Length:126
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Protein-Protein Interactions as a Strategy towards Protein-Specific Drug Design: The Example of Ataxin-1.
Plos One 8 e76456 e76456 (2013)
PMID: 24155902 DOI: 10.1371/journal.pone.0076456

Abstact

A main challenge for structural biologists is to understand the mechanisms that discriminate between molecular interactions and determine function. Here, we show how partner recognition of the AXH domain of the transcriptional co-regulator ataxin-1 is fine-tuned by a subtle balance between self- and hetero-associations. Ataxin-1 is the protein responsible for the hereditary spinocerebellar ataxia type 1, a disease linked to protein aggregation and transcriptional dysregulation. Expansion of a polyglutamine tract is essential for ataxin-1 aggregation, but the sequence-wise distant AXH domain plays an important aggravating role in the process. The AXH domain is also a key element for non-aberrant function as it intervenes in interactions with multiple protein partners. Previous data have shown that AXH is dimeric in solution and forms a dimer of dimers when crystallized. By solving the structure of a complex of AXH with a peptide from the interacting transcriptional repressor CIC, we show that the dimer interface of AXH is displaced by the new interaction and that, when blocked by the CIC peptide AXH aggregation and misfolding are impaired. This is a unique example in which palindromic self- and hetero-interactions within a sequence with chameleon properties discriminate the partner. We propose a drug design strategy for the treatment of SCA1 that is based on the information gained from the AXH/CIC complex.

Legend

Protein

Chemical

Disease

Primary Citation of related structures